AUTHORS
Rachael Grace, MMSc, MD, Michele P Lambert Jr, MD2, Matthew Foster, MD3, Jenny Despotovic, DO4, Justyna Fronczek-Sokol5, Patrick Urban, MD6, Karen Sinclair7, Nathalie Dupuy8, Julie Niolat9, Nichola Cooper, MD, FRCP, FRCPath, MA10
AFFILIATIONS
1 Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts, United States
2 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
4 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
5 Novartis Pharma AG, Basel, Switzerland
6 Novartis Pharma AG, Basel, Switzerland
7 Novartis Pharma AG, Basel, Switzerland
8 Novartis Pharmaceuticals UK Ltd., London, United Kingdom
9 Novartis Pharma, Rueil-Malmaison, France
10 Imperial College London, London, United Kingdom
ABSTRACT
Background
Immune thrombocytopenia (ITP) is a rare, acquired autoimmune disease characterized by a low platelet count and risk of bleeding. Although ITP may spontaneously resolve, 24-40% of children with ITP experience persistent disease and 20-30% develop chronic ITP. Current treatments rarely lead to durable, stable responses, especially after discontinuation. Autoreactive B cells, in part mediated by the B-cell activating factor receptor (BAFF-R), play a central role in ITP pathophysiology. Ianalumab is a monoclonal antibody targeting BAFF-R through a dual mechanism of enhanced B-cell depletion via antibody-dependent cytotoxicity and inhibition of B-cell activation and survival via BAFF-R blockade. The phase 3 VAYHIT2 study of ianalumab in adults with primary ITP who had an insufficient response to, or relapsed after, first-line corticosteroids demonstrated that a short course of ianalumab plus eltrombopag led to a significantly longer time to treatment failure (TTF) and higher rate of stable responses at 6 months than placebo plus eltrombopag, with a favorable safety profile (Cuker A, et al. NEJM. 2026; 394(15):1503-1513).
Aim
VAYHIT-P (NCT07660172) is a phase 2, open-label, multicenter, global, single-arm study assessing the efficacy, safety and pharmacokinetics of ianalumab plus eltrombopag in pediatric patients with primary ITP who have had an insufficient response to, or relapsed after, first-line corticosteroid treatment.
Methods
VAYHIT-P will enroll at least 36 patients. Eligible patients will be 5 to <18 years of age and have primary ITP. Patients must also have a platelet count <30 × 10?/L and be up to date on childhood vaccinations as per local vaccination schedules. Exclusion criteria include prior use of second-line ITP treatments; prior corticosteroids with or without intravenous immunoglobulin are permitted.
Patients will be divided into adolescents 12 to <18 years of age (Cohort 1) and children 5 to <12 years of age (Cohort 2). Eight to 10 patients will enroll in Cohort 1 and will receive 9 mg/kg ianalumab intravenous infusions every 4 weeks over a 24-week treatment period, in addition to eltrombopag. The dosing of ianalumab is initially based on an exposure-matching approach to the safe and effective dose in adults with ITP. Enrollment of those first 8-10 patients in Cohort 1 and analysis of their results will occur before opening enrollment for Cohort 2 as safety, efficacy and pharmacokinetics of ianalumab in these patients will support recommendations for dosing in both cohorts for the rest of the trial. Eltrombopag will be tapered in patients who maintain platelet counts ≥50 × 10?/L without rescue therapy between weeks 15-17. Tapering will occur between weeks 17-24 until discontinuation, as long as platelet counts remain ≥30 × 10?/L. Patients ineligible for eltrombopag tapering can continue receiving eltrombopag or start a new ITP treatment at the investigator’s discretion. After the treatment period, depending on efficacy observed, patients will enter either an efficacy and safety follow-up (until treatment failure or up to 39 months, whichever occurs first) or a safety-only follow-up (up to 2 years).
The primary endpoint is TTF, defined as the time from treatment initiation until any of the following: platelet counts <30 × 10?/L or start of rescue therapy beyond 8 weeks from treatment initiation; start of a new ITP therapy at any time; ineligibility to taper or discontinue eltrombopag; or all-cause mortality. Secondary endpoints include timing, depth, and duration of platelet responses, incidence and severity of bleeding and adverse events, need for rescue treatment, rates of successfully tapering and discontinuing eltrombopag, safety, pharmacokinetics, pharmacodynamics and immunogenicity of ianalumab. TTF and secondary time-to-event endpoints will be analyzed descriptively using the Kaplan-Meier method; other secondary endpoints will be summarized descriptively.
VAYHIT-P is not yet recruiting, with enrollment estimated to commence in 2027.
Conclusion
The phase 2 VAYHIT-P study will assess the efficacy, safety and pharmacokinetics of ianalumab plus eltrombopag in pediatric patients with primary ITP who had an insufficient response to, or relapsed after, first-line corticosteroids.
DISCLOSURES
Rachael Grace, MMSc, MD: Agios - Research Funding; Novartis - Research Funding; Sobi - Research Funding; Agios - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)